Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 439 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Obesity and Overweight
Interventions
GZR18, Tirzepatide
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Bessemer, Alabama • Centreville, Alabama • Little Rock, Arkansas + 16 more
Conditions
Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions
Gastric Ultrasound Exam
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 99 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, GlucaGen, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Gastric Bypass Surgery, Obesity
Interventions
Liquid Meal, Solid Meal
Other
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions
Metformin XR plus placebo, Metformin XR plus liraglutide
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Alcohol Use Disorder
Interventions
Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Havre de Grace, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

NCT01722266
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Williamsville, New York
Conditions
Diabetes type1, Obesity
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Type II
Interventions
Liraglutide, Insulin
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Asheville, North Carolina
Conditions
Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist, Insulin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
Conditions
Endometrial Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Wrinkle
Interventions
Skinvive
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Diego, California
Conditions
Lymphedema
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Advanced Reconstructive Surgery Alliance
Government
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Red Bank, New Jersey • Westwood, New Jersey
Conditions
Irritable Bowel Syndrome Constipation Predominant
Interventions
ROSE-010, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

NCT00947011
Conditions
Glucose Homeostasis
Interventions
Placebo, Januvia
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Nutrition Intake, Nutrition Status, Gastrointestinal Microbiome, GLP-1
Interventions
AG1 - Nutritional Supplement, Placebo
Dietary Supplement
Lead sponsor
Athletic Greens International
Industry
Eligibility
18 Years to 59 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type1diabetes
Interventions
Very low carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
Exendin-9,39, Saline
Biological · Other
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Type 2 Diabetes Mellitus
Interventions
OPTIFAST
Other
Lead sponsor
Moahad S Dar
Other
Eligibility
25 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Greenville, North Carolina
Conditions
Obesity & Overweight, Mobility Disability, HOMA-IR
Interventions
Enobosarm, Semaglutide (Wegovy) weekly injection
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
65 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Doral, Florida • Miami, Florida + 4 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

NCT04466618
Conditions
Healthy, Type 2 Diabetes
Interventions
Saline, Exendin-9,39, Saline + Intralipid/Heparin, Exendin-9,39 + Intralipid/Heparin
Biological
Lead sponsor
Adrian Vella
Other
Eligibility
25 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota